DUX4 and sarcoma: Thus, RNAi-based technologies and/or cell penetrating antibodies that can effectively target the DUX4 in the context of the CIC::DUX4 fusion can open another therapeutic avenue directed at selective targeting of the CIC::DUX4 oncoprotein in human sarcoma (Table 2).